Orthofix Medical Inc. OFIX recently announced the receipt of FDA 510(k) clearance and the first U.S. implant of the Fitbone Transport and Lengthening System. The system is used to treat large bone defects in the femur and tibia due to trauma or infectious or malignant conditions. The device is the only intramedullary nail intended to extend or transfer bone in a single surgical procedure. For treatments involving limb restoration and deformity repair, Orthofix Medical is the only orthopedic company that provides a full range of internal and exterior fixation options. The Fitbone Transport and Lengthening System is currently available in the United States under a limited market release. More on the News Patients with femur and tibia abnormalities are frequently difficult to treat and have had several procedures in the past. With the revolutionary new Fitbone Transport and Lengthening System, extremely difficult conditions can be fixed without the need for numerous follow-up procedures by allowing bone to be transferred across the defect. The Fitbone Transport and Lengthening System utilizes the same motorized technology as the Fitbone TAA Intramedullary Lengthening System, a clinically proven device with more than 20 years of use and multiple publications to back it. The motorized intramedullary nail, a receiver, and an external control set make up the device, which is implanted in a minimally invasive surgery and allows the patient to manage the distraction phase at home. The receiver and nail are taken out after the course of treatment is completed. More on Fitbone TAA Intramedullary Lengthening System The Fitbone TAA Intramedullary Lengthening System is intended for limb lengthening of the femur and tibia. With the combination of preoperative planning, specialist Fitbone instrumentation and the Fitbone lengthening nail, it is possible to make axial and torsional corrections as part of limb lengthening. The Fitbone Intramedullary Limb-lengthening System has been incorporated into the OrthoNext digital platform. The OrthoNext software features the reverse planning method module that simulates the target position, osteotomy level and blocking screw placement, enabling a more accurate preoperative assessment and optimized limb correction. Industry Prospects Per a report by Coherent Market Insights, the global orthopedic extension devices market was valued at $937.2 million in 2023 and is expected to witness a growth rate of 4% from 2023 to 2030. Given the market potential, Orthofix Medical is likely to generate additional revenues from the sale of its Fitbone Transport and Lengthening Systempost-FDA clearance. Notable Development In May, Orthofix announced the receipt of FDA 510(k) clearance to market its Rodeo Telescopic Nail. The nail implant is likely to stabilize the patient’s limb while also elongating (or telescoping) to accommodate the natural growth of pediatric patients. Price Performance In the past six months, OFIX’s shares have gained 4.2% compared with the industry’s rise of 1.9%. The S&P 500 increased 17.3% in the same time frame. Zacks Investment Research Image Source: Zacks Investment Research Zacks Rank & Stocks to Consider OFIX carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are DaVita DVA, Ecolab ECL and Universal Health Services UHS. DaVita, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. DaVita’s shares have gained 44% compared with the industry’s 20.4% growth in the past year. Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.7%. Ecolab’s shares have gained 33.8% against the industry’s 9.3% decline in the past year. Universal Health Services has an Earnings ESP of +2.91% and a Zacks Rank of 2, at present. UHS has an estimated earnings growth rate of 30.5% for 2024. UHS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.12%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ecolab Inc. (ECL):Free Stock Analysis Report Universal Health Services, Inc. (UHS):Free Stock Analysis Report DaVita Inc. (DVA):Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Orthofix Medical's (OFIX) Fitbone System Gets FDA Clearance
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...